Article
Multi-cohort, cross-species urinary proteomics reveals signatures of LRRK2 dysfunction in Parkinson's disease.
Molecular systems biology - 1 May 2026
Vu Duc Tung, Sibran William, Metousis Andreas, Vandewynckel Laurine, Eraslan Basak, Goveas Liesel, Itang Ericka Cm, Deldycke Claire, Figueroa-Garcia Adriana, Lefèbvre Réginald, Müller-Reif Johannes Bruno, Virreira Winter Sebastian, Chartier-Harlin Marie-Christine, Taymans Jean-Marc, Mann Matthias, Karayel Ozge
Abstract excerpt
Pathogenic mutations in Leucine-rich repeat kinase 2 (LRRK2) are the predominant genetic cause of Parkinson's disease (PD) and often increase kinase activity, making LRRK2 inhibitors promising treatment options. Although LRRK2 kinase inhibitors are advancing clinically, non-invasive readouts of LRRK2-linked pathway modulation remain limited. Profiling urinary proteomes from 1215 individuals across three cohorts...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.